Articles related to Oncology, Medical

HER2-Directed ADCs in Gastric Cancer Several antibody-drug conjugates (ADCs) have recently received approval for use in treating a range of solid cancers. This poses difficulties when handling a variety of adverse treatment-related events, some of which can take practitioners into uncharted area. After viewing this CME activity, medical oncologists, pulmonologists, urologists, pathologists, oncology NPs, PAs, oncology nurses, oncology pharmacists, and other HCPs caring for patients with solid tumors should be able to describe the elements of an antibody-drug conjugate (ADC) that may cause adverse events (AEs), identify AEs that result in treatment interruption or discontinuation, and suggest a strategy for managing the key AEs.

Patients with newly diagnosed acute myeloid leukemia (AML) have had better results thanks to alterations to cytarabine/anthracycline-based intense chemotherapy, including the addition of high-dose cytarabine and adjustments to the dosage schedule or type of anthracycline.

A compilation of each lymph node level’s radiologically practical bounds, which include: Submental and submandibular at Level I Level II: Deep cervical (internal jugular) chain Level III: deep cervical (internal jugular) chain Lower internal jugular (deep cervical) chain, level IV Posterior triangle at level V Central (anterior) compartment at level VI

In conclusion, daratumumab (Darzalex) (D) was added to lenalidomide, bortezomib, and dexamethasone (RVd) in NDMM patients who were transplant-eligible, and this led to enhanced stringent complete response (sCR) and minimal residual disease (MRD)-negative rates, a tolerable safety profile, and no clinically meaningful effects on stem cell mobilization or engraftment. These findings suggest that the D-RVd combination may become a new standard of care for NDMM who are transplant-eligible.

Acquired/congenital bone marrow failure, thalassemia/hemoglobinopathies, transfusion medicine, new therapies (pharmacology), infections of the immunocompromised, hematologic malignancies (acute/chronic leukemias; myeloma/lymphomas), thoracic oncology (head/neck/lung/thyroid), and many other practice improvement areas are covered in this CME activity worth up to 41.25 credits. The video curriculum starts at $1,795 in price.

Adjuvant olaparib (Lynparza) was linked with significantly longer life free of invasive or distant illness compared to placebo among patients with high-risk, HER2-negative early breast cancer and germline BRCA1 or BRCA2 pathogenic or possibly pathogenic mutations. Global patient-reported quality of life was not significantly impacted by olaparib.